Kiniksa Pharmaceuticals International (KNSA) Jefferies London Healthcare Conference 2024 summary

ARCALYST commercial performance and growth

• ARCALYST has achieved 74% year-on-year growth in Q3, with sequential gains following a strong Q2.

• Sales force expanded from 29 to 85 representatives, driving 11% penetration in a 14,000-patient target group.

• Over 2,550 unique prescribers have launched to date, with prescriber numbers growing by 250 in Q3.

• Payer approval rates exceed 90%, and average treatment duration increased to 27 months.

• 85% of patients are treated after two or more recurrences, with 15% now on first recurrence, indicating label breadth.

Market opportunity and commercial strategy

• The addressable population could expand from 14,000 to 40,000 by targeting earlier-stage patients.

• Commercial efforts are agnostic to academic or community settings, focusing on patient throughput and physician reach.

• About 70% of prescribing is by cardiologists, with the remainder mainly by rheumatologists.

• Kiniksa OneConnect supports patients and providers, enhancing the prescribing experience.

• Capital allocation and sales force size are managed analytically to maximize returns and profitability.

Pipeline and business development

• CD40 program abiprubart is in phase IIb for Sjögren's disease, testing biweekly and monthly dosing.

• The program leverages a high-concentration liquid formulation for convenient dosing.

• No specific timelines disclosed for data readout; primary endpoint is at 24 weeks.

• Business development remains a priority, with a high bar for new assets and ongoing outlicensing activities.

• Ex-US expansion for ARCALYST is under consideration, with orphan designation in Europe.